US Pharmaceutical Contract Manufacturing Market to Reach $115.7 Billion by 2035

US pharmaceutical contract manufacturing market was valued at $52.5 billion in 2025 and is projected to reach $115.7 billion by 2035, growing at a CAGR of 6.4% during the forecast period (2026–2035).  The US pharmaceutical contract manufacturing market is witnessing strong capacity expansion and sustained capital inflows across the value chain. In 2025, approximately $24.8 billion has been invested in CDMO capacity, with nearly 74% of this investment directed toward the United States, highlighting its growing role in global pharmaceutical manufacturing. This investment activity is primarily focused on large-scale infrastructure development, including Greenfield facilities, site expansions, and advanced bio manufacturing hubs. These developments are strengthening the country’s position as a leading center for high-value drug production and innovation-led manufacturing. Major pharmaceutical companies are increasing multi-billion-dollar commitments to expand domestic production capabilities and secure long-term supply resilience. For instance, Johnson & Johnson has announced substantial investments to enhance its U.S. manufacturing network. At the same time, CDMOs are expanding their footprint to support growing demand for biologics, sterile injectable, and complex therapies. The rise in capacity additions is also intensifying competition among CDMO providers as they compete for large global outsourcing contracts. Greenfield facilities are playing a key role by enabling companies to establish fully integrated, modern manufacturing sites with advanced technologies. Site expansions are helping existing facilities increase output and improve operational efficiency. Bio manufacturing hubs are also being developed to support next-generation therapies such as cell and gene treatments. Together, these investments are reinforcing the United States as a preferred destination for pharmaceutical production. The market is increasingly characterized by strategic collaborations between pharma companies and CDMOs. Overall, this wave of capacity expansion is reshaping the manufacturing landscape and strengthening the country’s global competitiveness.

Browse the full report description of “US Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report by Service (API Manufacturing, FDF Manufacturing, Fill?Finish & Packaging Services, and Other), By Product (Small Molecules, and Biologic Products), By End-User (Batch Manufacturing, Continuous Manufacturing, Single?Use Technology Lines, Advanced Bioprocess Systems), Forecast Period 2026-2035” at https://www.omrglobal.com/industry-reports/us-pharmaceutical-contract-manufacturing-market

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • Service
  • By Product
  • Manufacturing Process
• Competitive Landscape - Thermo Fisher Scientific Inc. (Patheon Pharma Services), Lonza Group AG, Catalent, Inc., Pfizer CentreOne, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

US Pharmaceutical Contract Manufacturing Market Report Segment

By Service

• API Manufacturing
• FDF Manufacturing
• Fill?Finish & Packaging Services
• Other

By Product

• Small Molecules
• Biologic Products

By Manufacturing Process

• Batch Manufacturing
• Continuous Manufacturing
• Single?Use Technology Lines
• Advanced Bioprocess Systems

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/us-pharmaceutical-contract-manufacturing-market